Novavax, Inc [NASDAQ: NVAX] plunged by -$0.02 during the normal trading session on while it closed the day at $8.53.
Novavax, Inc stock has also loss -11.19% of its value over the past 7 days. However, NVAX stock has declined by -32.30% in the 3 months of the year. Over the past six months meanwhile, it has lost -46.18% and gained 6.09% year-on date.
The market cap for NVAX stock reached $1.37 billion, with 160.15 million shares outstanding and 152.99 million shares in the current float. Compared to the average trading volume of 5.28M shares, NVAX reached a trading volume of 3890724 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Novavax, Inc [NVAX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NVAX shares is $16.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NVAX stock is a recommendation set at 2.33. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JP Morgan have made an estimate for Novavax, Inc shares, keeping their opinion on the stock as Underweight, with their previous recommendation back on July 30, 2024. The new note on the price target was released on May 10, 2024, representing the official price target for Novavax, Inc stock. Previously, the target price had yet another raise from $4 to $12, while BofA Securities kept a Neutral rating on NVAX stock.
The Average True Range (ATR) for Novavax, Inc is set at 0.65, with the Price to Sales ratio for NVAX stock in the period of the last 12 months amounting to 1.54.
NVAX stock trade performance evaluation
Novavax, Inc [NVAX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -11.19. With this latest performance, NVAX shares dropped by -6.37% in over the last four-week period, additionally sinking by -46.18% over the last 6 months – not to mention a rise of 96.54% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NVAX stock in for the last two-week period is set at 46.15, with the RSI for the last a single of trading hit 44.26, and the three-weeks RSI is set at 46.41 for Novavax, Inc [NVAX]. The present Moving Average for the last 50 days of trading for this stock 8.68, while it was recorded at 8.70 for the last single week of trading, and 10.82 for the last 200 days.
Novavax, Inc [NVAX]: An insightful look at the core fundamentals
Novavax, Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.93 and a Current Ratio set at 0.93.
Novavax, Inc [NVAX]: Institutional Ownership
There are presently around $60.00%, or 62.77%% of NVAX stock, in the hands of institutional investors. The top three institutional holders of NVAX stocks are: VANGUARD GROUP INC with ownership of 14.08 million shares, which is approximately 10.0599%. BLACKROCK INC., holding 11.85 million shares of the stock with an approximate value of $$149.98 million in NVAX stocks shares; and BLACKROCK INC., currently with $$122.32 million in NVAX stock with ownership which is approximately 6.9056%.
